A framework for the classification of joint hypermobility and related conditions.
Marco Castori, Brad Tinkle, Howard Levy...
https://pubmed.ncbi.nlm.nih.gov/28145606/Actively Recruiting
Led by Medical College of Wisconsin · Updated on 2026-02-13
90
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying Hypermobile Ehlers-Danlos Syndrome hEDS, a connective tissue disorder that causes very flexible skin and joints, along with other tissue issues. This condition often comes with gastrointestinal and autonomic nervous system problems, such as postural orthostatic tachycardia syndrome POTS. The study explores the link between hEDS and autonomic regulation and evaluates if two types of non-invasive vagal nerve stimulation therapies can reduce gastrointestinal symptoms in people with hEDS and POTS. It also examines how these therapies might affect stomach function and nerve signaling. The study involves two groups of participants. One group of 60 children with hEDS or Hypermobile Spectrum Disorder will participate in a four-week, randomized, double-blind trial listening to either special filtered vocal music designed to stimulate vagal nerve calming active therapy or regular music sham therapy. The other group of 30 children with autonomic nervous system dysfunction will receive a six-week open-label treatment using a device called IB-Stim, which provides low voltage nerve stimulation through electrodes on the ear. Some participants may also undergo a gastric MRI scan and provide blood samples for additional research. Participants will be assessed before, during, and after therapy using questionnaires about gastrointestinal symptoms, body perception, and nerve function. The study measures changes in these symptoms and uses imaging to observe stomach motor function. Monitoring includes questionnaires and physiological tests over about six weeks of therapy. The trial runs until the end of 2026, and researchers will review outcomes like symptom improvement and nerve efficiency to understand effects of these therapies on hEDS and related autonomic issues.
CONDITIONS
Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
K
Katja Karrento, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical College of Wisconsin
Lead Sponsor
University College, London
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Percutaneous Vagal Nerve Stimulation (IB-Stim Device) | Acoustic Vagal Nerve Stimulation (aVNS) Therapy |
|---|---|---|
| What it is | Percutaneous vagal nerve stimulation delivered by the IB-Stim device, an externally affixed, battery-powered neurostimulation system with electrode arrays on the ear that provide continuous low-voltage stimulation. | Acoustic vagal nerve stimulation (aVNS) using digitally processed vocal music designed to enhance vagal calming, played via electronic devices in sessions delivered either as the Safe and Sound Protocol or non-filtered music in an active therapy setting. |
| Role in trial | Active comparator arm testing efficacy of the IB-Stim percutaneous auricular device in children with upper gastrointestinal symptoms and suspected hEDS or ANS dysfunction. | Experimental arm evaluating efficacy of active acoustic vagal nerve stimulation therapy for the same target population. |
| Primary use | Intended to improve functional gastrointestinal symptoms in pediatric patients with hypermobile Ehlers-Danlos syndrome or suspected autonomic nervous system dysfunction. | Intended to reduce functional upper gastrointestinal symptoms in the same pediatric group through music-based stimulation designed to induce vagal calming effects. |
| How it is given or performed | The IB-Stim device is attached to the external ear and delivers continuous low-voltage stimulation alternating at preset frequencies for 5 days per treatment cycle, over a six-week open-label trial period. | Music-based aVNS is administered via electronic devices (e.g., smartphone, tablet, laptop) with sessions led virtually by trained coaches, over a four-week course, using specifically processed music to stimulate the vagal pathway. |
| Evidence status | Prior studies, including randomized controlled trials, have shown that percutaneous vagal nerve stimulation with IB-Stim may help adolescents with abdominal pain-related functional GI disorders, but effectiveness specifically in pediatric hEDS/ANS populations requires further study. | Pilot research and small-scale clinical studies suggest that acoustic-based vagal nerve stimulation may modulate autonomic function and improve GI symptoms, but robust large-scale evidence in pediatric GI and hEDS/ANS populations remains limited and is being actively investigated. |
| Important limitations | The effectiveness and safety of IB-Stim for treating functional GI symptoms in pediatric patients with hEDS or ANS dysfunction are not yet established. Prior studies focused on broader functional GI disorders, and this subpopulation may differ. | Existing evidence for aVNS, including Safe and Sound Protocol, is limited by small cohorts and lack of randomized controlled trials in this patient population. The benefits described are preliminary and need confirmation in larger studies. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 to 6 weeks
Participants receive one of two non-invasive vagal nerve stimulation therapies aimed at reducing gastrointestinal symptoms and improving autonomic regulation: either acoustic vagal nerve stimulation via filtered vocal music played virtually over four weeks, or percutaneous vagal nerve stimulation using an ear-attached device worn continuously for 5 days within a six-week treatment period.
Weekly visits for up to 6 weeks
Duration - Up to 6 weeks after treatment
Participants may undergo additional assessments including gastric MRI scans and blood sample collection if enrolled in sub-studies, to evaluate gastric motor function and biological markers after treatment ends.
1 to 2 additional visits depending on sub-study participation
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Marco Castori, Brad Tinkle, Howard Levy...
https://pubmed.ncbi.nlm.nih.gov/28145606/Yael Gazit, A Menahem Nahir, Rodney Grahame...
https://pubmed.ncbi.nlm.nih.gov/12867232/Katja Kovacic, Keri Hainsworth, Manu Sood...
https://pubmed.ncbi.nlm.nih.gov/28826627/Stephen W Porges, Maria I Davila, Gregory F Lewis...
https://pubmed.ncbi.nlm.nih.gov/30868570/Katja Kovacic, Thomas C Chelimsky, Manu R Sood...
https://pubmed.ncbi.nlm.nih.gov/25151198/Medical College of Wisconsin
Lead Sponsor
University College, London
Collaborating Sponsor